I just have to say Craig… that optimist hat you use to
I just have to say Craig… that optimist hat you use to wear once in a great while… You must of thrown it on the ground and stopped it until it cried for you to stop and then for good measure you stopped it again and again until you couldn’t tell it was even a hat.
You sir have been the pessimist of the board lately. You use to have that streak of show me the facts but now it’s all poo poo this and poo poo that.
As for Nader being the man. If everything goes as we would expect it to. Nader stays in charge and our first approval happens before April 2022. I would say that “Nader is our man” he brought us this funny MAB drug that we thought might be just for HIV and somehow it is the Jack of all trades for many diseases or so it seems. Nader having found it and pushed the narrative of what it can do and trialed it to a successful trial in HIV and possibly something even sooner in a possible covid EUA.
I ask you how you can’t see that it’s all Nader leading this miraculous drug to its first approval? Is there someone else that should be getting the majority of the credit? I know there is a management team and I take nothing away from the help that Nader has received. But Nader has been the chosen one to bring us this far and it looks more and more like he is the one to get us across the finish line. The 13d is timing out and failing in their bid as it looks currently.
Why… because the 13d doesn’t stand a chance with their “no plan” effort at BASHING their way into control of a drug that will make it to market with or without them. They have nothing to offer us. The 13d group would bring us nothing and only slow us down. Why would we trust such a shit show as they have been? It’s almost a joke that they still trying after their legal mess they presented in their initial filings. We are in court because they didn’t file open and honestly. Yet, they still believe they can capture our trust. What pipe are they hitting. It’s not tobacco. My opinions could go on and on about their worthlessness. Unless you would like to mention something I left out about that investor group? Something pertinent that might capture them a few votes that they could earn from say a pessimist?
10
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...
Continue Reading
Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...
Continue Reading
Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...
Continue Reading
A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...
Continue Reading
Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...
Continue Reading
Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...
Continue Reading
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading
Top 5 Most Recently Viewed Articles
Frost & Sullivan Institute: Leading By Example Alright, folks, we’re talking about the kind of business leadership that isn’t just about fattening the bottom line. The Frost & Sullivan Institute rolled out the carpet for companies that don’t just talk the talk—they walk the walk. This recognition isn't just another plaque for the wall; it's a pat on the back for...
Continue Reading
Revolutionizing Franchise Excellence: The Plus Games Batteries Plus, a leader in the battery retail sector, has embarked on an exciting journey with its newly announced initiative called The Plus Games. This program is designed to transform franchisee training and sales strategies by gamifying the entire process. The objective? To cultivate exceptional performance and...
Continue Reading
Investigation into Eos Energy Enterprises Pomerantz LLP is currently investigating claims concerning investors of Eos Energy Enterprises, Inc. (NASDAQ: EOSE). This inquiry raises questions about whether the company and some of its executives may have been involved in securities fraud or other fraudulent business practices. Recent Developments at Eos Energy Recently, Eos...
Continue Reading
Impact of Millennial Preferences on Cold Brew Coffee The cold brew coffee market is poised for significant growth, estimated to expand by USD 519.2 million within the forecast period. This growth is largely driven by changing consumer preferences, particularly among millennials who favor modern, convenient beverage choices. As more companies enter the market with...
Continue Reading
EMCOR Group, Inc. Announces Quarterly Cash Dividend NORWALK, Conn. - EMCOR Group, Inc. (NYSE: EME) has proudly declared a regular quarterly cash dividend of $0.25 per common share. This announcement was made by the Board of Directors, showing their ongoing commitment to delivering value to shareholders. Dividend Payment Details The scheduled payment date for the upcoming...
Continue Reading